Factory Mutual Insurance Co. Decreases Stock Position in AbbVie Inc. $ABBV

Key Points

• Factory Mutual Insurance Co. lowered its stake in AbbVie by 20.6%, selling 48,150 shares and retaining 185,150 shares worth about $42.3 million per its latest SEC filing.
• AbbVie cut its Q1 and FY2026 EPS guidance (Q1: $2.560–2.600 vs. consensus ~3.01; FY: $13.960–14.160 vs. consensus ~14.56), a primary near‑term negative catalyst for the stock.
• Senior executives recently sold shares (EVP Perry C. Siatis sold 22,381 shares at ~$230; SVP David R. Purdue sold 5,230 shares at ~$233.56), and corporate insiders now own only about 0.06% of the stock.

Factory Mutual Insurance Co. lowered its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 20.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 185,150 shares of the company's stock after selling 48,150 shares during the period. Factory Mutual Insurance Co.'s holdings in AbbVie were worth $42,305,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company's stock worth $41,155,601,000 after buying an additional 448,554 shares during the period. Legal & General Group Plc increased its holdings in shares of AbbVie by 4.3% in the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company's stock worth $2,779,426,000 after buying an additional 493,420 shares during the period. Wellington Management Group LLP increased its holdings in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the period. Amundi increased its holdings in shares of AbbVie by 15.6% in the third quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. increased its holdings in shares of AbbVie by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock worth $2,241,363,000 after buying an additional 408,426 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

Insider Buying and Selling

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie's successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie's guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie's guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

AbbVie Price Performance

Shares of NYSE:ABBV opened at $208.22 on Friday. AbbVie Inc. has a 1 year low of $168.54 and a 1 year high of $244.81. The company has a market cap of $368.16 billion, a PE ratio of 88.23, a P/E/G ratio of 0.76 and a beta of 0.38. The stock's 50-day moving average is $220.35 and its 200 day moving average is $224.01.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the business earned $2.16 EPS. The business's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie's dividend payout ratio is 293.22%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ABBV. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a report on Saturday. The Goldman Sachs Group restated a "neutral" rating and set a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Weiss Ratings restated a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Cantor Fitzgerald reduced their price target on AbbVie from $250.00 to $240.00 and set an "overweight" rating on the stock in a report on Wednesday. Finally, William Blair restated an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and a consensus price target of $253.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.